Cashu
Redhill Biopharma's Commitment to Innovative Treatments and Strategic Partnerships in Healthcare
3 days ago
Stocks
Health Care
rdhl
Redhill Biopharma
NASDAQ: RDHL
-0.06 (-4.08%)
1.375
USD
At close at Sep 08, 14:40 UTC
Overview
Loading chart...
Key Stats
Market Cap
-
Dividend Yield
0.00%
P/E Ratio
0.00
EPS
0.23
Revenue
18.95M
Avg. Volume
50.03K
About
What does RDHL do?
RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.